The melastatin-related transient receptor potential member 7 (TRPM7) is a unique fusion protein with both ion channel function and enzymatic α-kinase activity. TRPM7 is essential for cellular systemic magnesium homeostasis and early embryogenesis; it promotes calcium transport during global brain ischemia and emerges as a key player in cancer growth. TRPM7 channels are negatively regulated through G-protein-coupled receptor-stimulation, either by reducing cellular cyclic adenosine monophosphate (cAMP) or depleting phosphatidylinositol bisphosphate (PIP 2 ) levels in the plasma membrane. We here identify that heterologous overexpression of human TRPM7-K1648R mutant will lead to disruption of protease or purinergic receptor-induced calcium release. The disruption occurs at the level of G q , which requires intact TRPM7 kinase phosphorylation activity for orderly downstream signal transduction to activate phospholipase (PLC)β and cause calcium release. We propose that this mechanism may support limiting GPCR-mediated calcium signaling in times of insufficient cellular ATP supply.
Introduction
The transient receptor potential melastatin 7 (TRPM7) is a member of the melastatin-related subfamily of TRP channels. The protein is unique in that it has both ion channel function and enzymatic α-kinase activity, with the ion transport domain in the N-terminal, and serine/threonine protein kinase domain in the C-terminal. TRPM7 is ubiquitously expressed and is essential for a variety of biological and physiological processes as well as early embryonic development (reviewed in [1] ). TPRM7 protein promotes magnesium (Mg 2+ ) transport into cells via its channel domain and is essential for cellular Mg 2+ homeostasis. Importantly, TRPM7 is reported as a regulator of cell proliferation, apoptosis, and differentiation, and therefore TRPM7 is considered as a key player in various diseases that include brain ischemia and cancer.
TRPM7 is negatively regulated by intracellular Mg 2+ and physiological amounts of adenosine triphosphate (Mg·ATP) [2] [3] [4] . A loss of TRPM7 kinase function leads to desensitization of TRPM7 to its intracellular inhibitors [5] . Enzymatic activity of the TRPM7 kinase is not required for the TRPM7 channel, rather, the binding of Mg·ATP to the kinase domain is required for phosphorylation of other protein targets. At the same time, the intrinsic kinase is a regulatory domain affecting TRPM7 ion conductance [5] [6] [7] . For example, TRPM7 activity is modulated by its kinase via protein kinase A (PKA) signaling, responding to changes in intracellular cyclic adenosine monophosphate (cAMP) levels through G i and G s -coupled receptors [8] . In addition, muscarinic type 1 (M1) G-protein-coupled receptor (GPCR) stimulation 1 3
regulates TRPM7 through activating phospholipase (PLC) β via G q . This leads to depletion of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) in the plasma membrane and inhibition of TRPM7 [9, 10] . Few phosphorylation substrates of the TRPM7 kinase are known, amongst them are annexin A1, eukaryotic elongation factor, myosin IIA, phospholipase C (PLC)β and PLCγ, as well as histones [1, 11] . Thrombin, a serine protease coagulation factor, binds to protease-activated receptor-1 (PAR-1), which is a member of a family of four GPCRs (reviewed in [12, 13] ). This induces a conformational change in PAR-1 leading to the separation of the Gα and the Gβγ subunits of the G-protein and further downstream signaling. PAR-1 preferentially couples to G q , leading to PLC-mediated inositol trisphosphate (InsP 3 ) production and intracellular calcium (Ca 2+ ) release. Thrombin can also bind to PAR-4. While PAR-1 causes fast and transient Ca 2+ release, PAR-4 induces slowly increasing intracellular Ca 2+ levels (reviewed in [14] ). PARs are ubiquitously expressed throughout mammalian tissue, and the physiological role of particularly PAR-1 includes platelet aggregation, endothelial barrier disruption and smooth muscle cell proliferation [12] . PAR-1 is an emerging therapeutic target in cancer [13] . Trypsin, an alternate serine protease, primarily activates GPCRs through PAR-2 binding [15] .
We previously reported that HEK293-TREx cells heterologously overexpressing mouse TRPM7 (mTRPM7) did not respond with a Ca 2+ release transient to thrombin stimulation, although control cells did [8] . Here, we set out to investigate how human TRPM7 (hTRPM7) interferes with thrombin-induced receptor stimulation. We find that the phosphorylation activity of the hTRPM7 kinase regulates G q , thereby controlling downstream signaling events of this heterotrimeric G-protein.
Materials and methods

Cell culture
Tetracycline (Tet)-inducible HEK293-TREx cells stably transfected with HA-tagged human TRPM7 wild type (hTRPM7) and the phosphotransferase activity-deficient point mutation in the hTRPM7 kinase domain, K1648R [5] , were cultured in DMEM medium (Sigma, USA) containing 10% fetal bovine serum (FBS) (Corning, USA), blasticidin (5 μg/ml) (Gibco, USA), and zeocin (0.4 mg/ml) (Gibco). Overexpression was induced adding 1 μg/ml tetracycline (Gibco) to the culture medium. Patch-clamp current measurements were performed 0-20 h post-tetracycline induction. Cells were maintained at 37 °C under 95% air and 5% CO 2 conditions.
Electrophysiology
For whole-cell patch-clamp technique assessing overexpressed hTRPM7 in Fig. 1 Patch-clamp experiments were performed in the wholecell configuration and combined with concomitant Fura-2 single cell Ca 2+ imaging [16] . TRPM7 currents were elicited by a ramp protocol from − 100 to + 100 mV from a holding potential of 0 mV over 50 ms and acquired at 0.5 kHz. Inward current amplitudes over the course of the experiment were extracted at − 80 mV, outward currents at + 80 mV and plotted versus time. Data were normalized to cell capacitance measured immediately after whole-cell break-in as pA/pF. Capacitance was measured using the automated capacitance cancellation function of the EPC-9 (HEKA, Lambrecht, Germany). All values are given as mean ± standard error of mean (SEM). Patch pipettes (Sutter Instrument, USA) were pulled and polished, and had a tip resistance of 2-3 MΩ with the solutions used. For fluorescence measurements, the ratiometric Ca 2+ dye Fura-2 was excited at 360 and 380 nm using an ITC-16 analog-digital board (Instrutech, USA), and X-Chart software (HEKA, Germany) controlling a monochromatic mirror grid (TILL Photonics, Germany). Fura-2 emission was captured using a custom-build photomultiplier tube from Hamamatsu Photonics, KK. Data were acquired at 5 Hz.
Western blot
To induce expression of HA-tagged human TRPM7 wildtype (hTRPM7) or K1648R mutant (hTRPM7-K1648R), 1 μg/ml tetracycline was added to the media for 5, 10, 15, 20 h. The cells were harvested and dissolved in RIPA buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% Triton X-100 and 0.5% sodium deoxycholate) containing a protease inhibitor cocktail (104 mM AEBSF, 80 μM Aprotinin, 4 mM Bestatin, 1.4 mM E-64, 2 mM Leupeptin and 1.5 mM Pepstatin A: Sigma-Aldrich, USA) for 30 min at 4 °C. Noninduced cells represent 0 h induction. After incubation for 30 min, the lysates were centrifuged at 13,000 rpm for 15 min at 4 °C and the protein concentrations of the lysates were measured using a protein assay reagent (BioRad Laboratories, USA). Soluble lysates were boiled with NuPAGE LDS sample buffer (Invitrogen, USA) at 98 °C for 5 min. Equal amounts of protein (100 μg) was loaded and separated by NuPAGE 3-8% gel (Invitrogen) and transferred to a PVDF membrane. Protein was detected by immunoblotting using the antibodies of rat monoclonal anti-HA (3F10, Roche, Switzerland), mouse monoclonal anti-GAPDH (6C5, Abcam, UK) and followed by treatment with IRDye infrared fluorescence-conjugated antirat and anti-mouse secondary antibodies (LI-COR, USA). GAPDH was evaluated as an internal control. Antibodybound protein was visualized using Odyssey CLx Imaging System (LI-COR). [5] ) were subjected to combined voltage-clamp and Fura-2 measurements to assess whole-cell currents and intracellular Ca 2+ changes. Voltage ramps were given from − 100 to + 100 mV over 50 ms. Current amplitudes were extracted at − 80 and + 80 mV, normalized to cell size in pF, averaged and plotted versus time of the experiment. As indicated by the black bars, 20 U thrombin, added to an external standard solution in 0 mM Ca 
Fluorescent 96-well or 384-well kinetic plate reader assay
To detect the optimal thrombin concentration for receptorstimulated calcium release, a state-of-the-art 96-well fluorescent kinetic plate reader was used (Hamamatsu FDSS-7000EX, Hamamatsu Photonics KK, Japan). Our TRPM7 screening assay developed for the FLEX station (Molecular Devices, USA; [17] ) was adapted to the FDSS-7000EX the following way: hTRPM7-HEK293-TREx cells (100,000 cells/well) were plated in poly-l-lysine-coated black 96-well plates with clear bottom (Greiner, Monroe, NC, USA) and induced by 1 μg/ml tetracycline after 5 h of cell plating. After 18 h of tetracycline post-induction, the culture medium was removed, replaced with Krebs-Ringer-HEPES (KRH) buffer supplemented with 2 μM Fura-2 AM (Invitrogen), 0.4% pluronic F-127 (Sigma-Aldrich) and incubated at 37 °C for 1 h. The plates were washed three times with KRH buffer after Fura-2 AM incubation, fresh KRH buffer was added, and plates were transferred to the FDSS-7000EX. Fura-2 was excited using 340 and 380 nm wavelengths and their ratio plotted versus time to observe changes in intracellular Ca For the 384-well plate assay, hTRPM7-HEK293-TREx cells and hTRPM4 HEK293-TREx cells (20,000 cells/well) were plated in poly-l-lysine-coated black 384-well plates with clear bottom (Greiner) and induced by 1 μg/ml tetracycline after 5 h of cell plating. After 20 h of tetracycline induction, the culture medium was removed, replaced with DMEM containing 10% FBS supplemented with 2 μM Fura-2 AM, 0.4% pluronic F-127, 2 mM probenecid and incubated at 37 °C for 1 h. The plates were washed three times with standard external solution after Fura-2 AM incubation, fresh buffer added, and transferred to the FDSS-7000EX. Intracellular Ca 2+ levels were measured by the same protocol as for the 96-well. Trypsin, NECA, ATP and ADP were diluted in standard external solution without Ca 2+ and applied after 1 min of starting to measure intracellular Ca 2+ by the FDSS-7000EX. Standard external solution contained (in mM): 140 NaCl, 2.8 KCl, 2 MgCl 2 , 20 HEPES-NaOH, 5.6 Glucose, 2 probenecid.
Statistical analysis
Patch-clamp data were acquired with PatchMaster software (HEKA, Germany) and exported to IGOR Pro (Wavemetrics, USA). Current amplitudes were extracted from IGOR Pro where all values for mean, standard deviation and standard error of the mean were calculated. In some cases p values based on two-tail, paired Student's T tests were calculated (IGOR Pro, Wavemetrics, USA).
Results
Heterologous overexpression of human TRPM7 inhibits G-protein receptor-coupled Ca 2+ release
Although the kinase domain of TRPM7 has been reported to bind phospholipase C (PLC), this interaction does not seem to influence TRPM7 channel activity per se. Rather, TRPM7 channel conductance is inhibited by depletion of phosphatidylinositol bisphosphate (PIP 2 ) in the plasma membrane upon activation of PLCβ [9, 10, 18] . Since PLC does not seem to directly influence TRPM7 channel activity, and receptor-induced calcium (Ca 2+ ) release appears altered in TRPM7-overexpressing cells [8] , we wondered whether the PLC-kinase interaction might cause changes in receptor-stimulated Ca 2+ signaling. We performed combined whole-cell patch-clamp and Fura-2 fluorescence experiments in HEK293-TREx cells overexpressing human TRPM7 (hTRPM7-HEK293) to assess changes in intracellular calcium [16] . hTRPM7-HEK293 were either left untreated or exposed to tetracycline for 10 min up to 18 h before whole-cell patch-clamp experiments (Fig. 1) . The intracellular solution was supplemented with 0.3 mM guanosine triphosphate (Na·GTP) and 200 µM Fura-2, but did not contain any supplemented adenosine triphosphate (Mg·ATP) to maximize TRPM7 current amplitudes (see "Materials and methods"). TRPM7 currents were allowed to develop fully before application of 20 U thrombin (in the absence of extracellular Ca 2+ ) between 200 and 280 s. Non-induced hTRPM7-HEK293 cells developed endogenous TRPM7-like currents that were not inhibited by thrombin application, and responded to thrombin stimulation with a fast and large Ca 2+ release transient from a flat baseline (Fig. 1a) . Induction of hTRPM7 overexpression after 8 h (Fig. 1b ) and 18 h (Fig. 1c) showed a steady increase in the intracellular Ca 2+ baseline in parallel with increased hTRPM7 current amplitudes (Fig. 1d) , and a clear, although diminished thrombininduced Ca 2+ transient. Plotting averaged peak TRPM7 currents (assessed at 400 s) and averaged peak Ca 2+ release by thrombin over tetracycline induction time revealed an inverse relationship between hTRPM7 current magnitude and the ability of thrombin to cause significant Ca 2+ release (Fig. 1e) . Note that the difference of peak release amplitude (Fig. 1a, lower panel; 1b, lower panel) and first Ca 2+ release data point (Fig. 1e) is because the peak release does not occur at exactly the same time in each cell. This broadens the release transient and reduces the apparent peak release.
Maximal currents were obtained after 14 h induction time, whereas receptor-induced Ca 2+ release was almost completely suppressed after 12 h of tetracycline exposure. In addition, the number of cells responding with Ca 2+ release to thrombin stimulation also decreased with longer induction times (Fig. 1f) . We conclude that overexpression of hTRPM7 perturbs thrombin-induced Ca 2+ signaling.
Thrombin-induced Ca 2+ release is dose-dependent
We next performed a dose-response experiment for thrombin using a fluorescent kinetic plate reader in the 96-well plate format allowing the measurement of fluorescence and see the real-time kinetic reactions of cells. Using the kinetic plate reader, we assessed thrombin-induced intracellular Ca 2+ changes in intact hTRPM7-HEK293 cells (see "Materials and methods"; Fig. 2a ). hTRPM7-HEK293 cells were either induced with tetracycline for 20 h (Fig. 2c) or not (Fig. 2b) , and exposed to various concentrations of thrombin diluted in extracellular solution without Ca
2+
. Analyzing the normalized 340/380 nm ratio over time, Ca 2+ release was impaired in hTRPM7 overexpressing cells compared to non-induced cells regardless of thrombin concentration (Fig. 2d) in analogy to our results obtained from combined whole-cell and Fura-2 patch-clamp experiments (Fig. 1) . A quantitative peak amplitude analysis revealed a concentration of 30 U thrombin as optimal for the induction of Ca 2+ release (Fig. 2d) . These data also confirmed that overexpression of hTRPM7 leads to a statistically significant suppression of thrombin-induced changes in cellular Ca 2+ regardless of agonist concentration (p < 0.05; Fig. 2d ) suggesting that this effect is not mediated by changes in receptor expression or agonist sensitivity.
Thrombin-induced Ca
2+ release requires both Mg·ATP and functional TRPM7 kinase activity One alternative possible reason for the decreased Ca 2+ release could be due to low intracellular Mg·ATP levels. In patch-clamped cells, the perfusion of Mg·ATP-free solutions will cause the diffusional escape of ATP into the pipette (Fig. 1) . In intact cells, the constitutive activity of TRPM7 could increase ATP consumption due to enhanced Ca 2+ pump activity to remove the TRPM7-mediated Ca 2+ influx (Fig. 2) . We therefore repeated the experiment shown in Fig. 1 , while adding 1.5 mM Mg·ATP to the intracellular (Fig. 3b, lower panel) ; (3) thrombin application now also inhibited hTRPM7 currents (Fig. 3b, upper panel) .
Since the TRPM7 atypical kinase domain requires Mg·ATP for its phosphorylation activity [7, 19] , we asked whether a functional TRPM7 kinase domain is required for thrombin-induced Ca 2+ release. To this end we investigated HEK293-TREx cells overexpressing hTRPM7-K1648R, which is a single-point mutation affecting the catalytic site of the kinase domain [5] . As shown by Western blot in Fig. 3a , tetracycline exposure induced overexpression of both hTRPM7 wild-type and hTRPM7-K1648R protein in a time-dependent manner (Fig. 3a) . Both protein species of TRPM7 increased in expression levels after 5 h of induction. In a next step, we investigated hTRPM7-K1648R with combined whole-cell patch-clamp and Fura-2 techniques using the same conditions as for hTRPM7 in Fig. 3b . Here, both TRPM7 current-inhibition and thrombin-induced Ca 2+ release were abolished in overexpressed hTRPM7-K1648R cells [5] (Fig. 3c) . Only one out of the 34 cells investigated retained thrombin-induced Ca 2+ release and concomitant current inhibition (Table 1 ). In addition, intracellular basal Ca 2+ levels were higher in the hTRPM7-K1648R mutant (Fig. 3c, lower panel) , possibly because these channels are less sensitive to intracellular Mg 2+ and Mg·ATP and therefore this mutant is constitutively more active than wild type channels [5] . We conclude that thrombin-induced Ca 2+ release requires intact TRPM7 kinase activity.
GTPγS rescues thrombin-induced Ca
2+ release independent of TRPM7 kinase activity Thrombin stimulates protease-activated receptors (PAR1, PAR3 and PAR4), which belong to the seven-transmembrane G protein-coupled family of receptors (GPCRs; reviewed in [12] ). Thrombin stimulation activates the phosphatidylinositol-signaling pathway through coupling to G q . Therefore, the absence of thrombin-induced Ca 2+ release in overexpressed TRPM7-K1648R mutants could be due malfunction of any 2+ release and TRPM7 kinase activity. HEK293-TREx cells overexpressing either human wild-type TRPM7 (TRPM7 WT), a TRPM7 mutant deficient in phosphotransferase activity (M7-K1648R), or human wild-type TRPM4 (TRPM4 WT) were investigated for Ca 2+ signals through protease-activated receptor stimulation using thrombin or trypsin, and metabotrophic purinergic-receptor stimulation using NECA, ADP or ATP. Ca 2+ release was assessed using a fluorescent kinetic plate reader in the 384-well format (see "Materials and methods").
The 340/380 nm ratio was normalized to 1 to the average of the 10 data points acquired before compound application in each of the 384 wells. The normalized ratio was then plotted against time of the experiment. The shaded areas indicate exposure to the respective agonists in extracellular solution absent of Ca
2+
: either thrombin (30 U), trypsin (100 nM), NECA (3 mM), ADP (3 mM) or ATP (3 mM) on a hTRPM7-WT (n = 4-8), b hTRPM7-K1648R (n = 4-8), c hTRPM4 (n = 4). Cells were either non-induced (tet-; black line) or induced for 20 h with tetracycline (tet + , red line) step in this signaling cascade, including perturbed refilling of intracellular Ca 2+ stores. To probe whether the signaling defect seen in hTRPM7 overexpressing cells was due to dysfunctional execution within the GPCR signaling cascade or interference with intracellular Ca 2+ store content, we took advantage of GTPγS (guanosine 5′-O-[gamma-thio] triphosphate), a non-hydrolysable heterotrimeric G protein-activating analog of guanosine triphosphate (GTP) [20] . Replacing 300 µM Na·GTP with 300 µM GTPγS in combined wholecell patch-clamp and Fura-2 experiments using hTRPM7-K1648R overexpressing HEK293-TREx cells (20 h induction time) caused both inhibition of hTRPM7 mutant currents (Fig. 3d, upper panel; 3e) as well as early Ca 2+ oscillations (Fig. 3d, lower panel) . Furthermore, additional stimulation of these cells with 30 U thrombin in Ca 2+ -free extracellular solution (see "Materials and methods") was now able to cause significant Ca 2+ release (Fig. 3d) . Thus, GTPγS is able to fully overcome the Ca 2+ release deficiency observed with kinase-mute hTRPM7-K1648R cells.
Protease-and purinergic receptor-induced Ca
2+
release and TRPM7 kinase activity Heterotrimeric G protein complexes are activated by a variety of GPCRs, including both PARs through, e.g., thrombin and trypsin, and metabotrophic purinergic receptors through ATP, adenosine diphosphate (ADP) or Adenosine (reviewed in [21] ). We wished to know whether the TRPM7 kinase specifically regulates thrombin-induced Ca 2+ release, or whether other GPCRs known to interact with G q would be affected as well. To this end we resorted to our fluorescent kinetic plate reader using the 384-well plate format to assess Ca 2+ signals in intact HEK293 cells that were either non-induced or induced with tetracycline for 20 h to overexpress either wild-type hTRPM7 (hTRPM7-HEK293) or the hTRPM7-K1648R mutant. Overexpression of human TRPM4 (hTRPM4) [16] , another melastatin family member, in HEK293-TREx induced by tetracycline for 20 h served as control to account for possible overexpression artifacts. To prevent unwanted artifacts due to Ca 2+ influx, extracellular Ca 2+ was absent from both the standard extracellular solution and the application solution containing the appropriate receptor agonist (30 U thrombin, 100 nM trypsin, 3 mM N-ethylcarboxamido adenosine (NECA), an adenosine receptor agonist, ATP or ADP; see "Materials and methods"; Fig. 4) . Analysis of the normalized 340/380 nm ratio under these conditions showed that of the additionally tested agonists only the protease receptor agonist trypsin had diminished Ca 2+ release when overexpressing hTRPM7 (Fig. 4a,  c) . Importantly, hTRPM4 overexpression did not interfere with Ca 2+ release by any of the tested agonists (Fig. 4c) . However, Ca 2+ was strongly reduced in overexpressing hTRPM7-K1648R cells when stimulating either purinergic GPCRs or protease-sensitive PARs. We conclude that an intact catalytic site within the hTRPM7 kinase domain is needed to provide feedback regulation for protease-and purinergic GPCR signaling.
Discussion
We here set out to identify how TRPM7 regulates heterotrimeric G protein-induced Ca 2+ release. We find that heterologous overexpression of human TRPM7 will lead to disruption of thrombin-induced Ca 2+ release unless an adequate intracellular Mg·ATP supply is guaranteed. The disruption occurs at the level of the heterotrimeric G-protein G q , which requires intact TRPM7 kinase phosphorylation activity for orderly downstream signal transduction resulting in Ca 2+ release induced by both protease-and purinergic agonists. We propose that this mechanism may contribute to the limitation of GPCR-mediated Ca 2+ signaling in times of insufficient cellular ATP supply.
TRPM7 is a constitutively active divalent cation channel with an enzymatically functional serine/threonine kinase domain. It is well known that free Mg 2+ and Mg·nucleotides, in particular Mg·ATP, suppress TRPM7 channel activity at physiologically relevant levels. The Mg·ATP binding site of the kinase domain has been well characterized (reviewed in [1] ). Because of the inhibitory action of Mg·ATP, most whole-cell patch-clamp experiments are conducted in the absence of both Mg 2+ and nucleotides to assure maximal current activation and reduce the signal-to-noise ratio. Both Mg·ATP and Mg·GTP are similarly effective in suppressing TRPM7 currents, however, physiologically significant Mg·GTP levels required for functional G-protein activation are in the lower millimolar range (~ 0.4 mM; [22] ), and therefore unlikely to significantly interfere with TRPM7 currents at those concentrations. However, overexpression of TRPM7 may lead to significant constitutive Ca 2+ entry triggering Ca 2+ pump activity and ATP consumption under the plasma membrane domain in intact cells.
Store-operated calcium entry is an important signaling mechanism in most immune and other electrically non-excitable cells (SOCE, reviewed in [23] ). Although TRPM7 is not a store-operated protein itself, it is synergistically interlaced with SOCE in the regulation of intracellular calcium homeostasis [24] . Experiments in DT40 B lymphocytes carrying various TRPM7 or Ca 2+ -release activated Ca 2+ (CRAC) channel mutations show that the TRPM7 kinase domain negatively regulates SOCE, possibly through stromal interaction molecule 2 (STIM2). In addition, the TRPM7 knock-out experiments show that the channel domain participates in the maintenance of endoplasmic reticulum Ca 2+ concentrations in resting cells [24] . While the former mechanism contributes to receptor-mediated Ca 2+ signaling, the latter is a homeostatic mechanism independent of receptor stimulation. In primary mouse mast cells, the TRPM7 kinase domain, but not the channel domain, appears to be involved in the regulation of GPCR-mediated stimulation in that it sets the Ca 2+ sensitivity of G protein-triggered mast cell degranulation and is essential for GPCR-activated histamine release [25] . The need for an active TRPM7 kinase domain has also been reported for G i/o , suppressing TRPM7 channel activity through modulating intracellular cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) [8] . In addition, we observed that overexpressing heterologous mouse TRPM7 (mTRPM7) in HEK293-TREx cells (16-22 h tetracycline induction) suppressed thrombin-induced Ca 2+ release without significantly affecting the filling status of intracellular Ca 2+ stores [8] . We therefore assessed the time course of this effect in overexpressed human TRPM7 (hTRPM7) using combined whole-cell patch-clamp and fluorimetric Ca 2+ measurements and made three important observations ( Fig. 1): (1) the proportion of cells responding to thrombin-stimulation decreased as a function of tetracycline-induced expression of hTRPM7; (2) the Ca 2+ release transients in responding cells and the increases in hTRPM7 currents were also temporally correlated and proceeded in parallel; and (3) basal Ca 2+ levels increased as hTRPM7 currents developed over induction time. Similar observations were made when stimulating intact cells using a 96-well kinetic plate reader to assess Ca 2+ signals induced by increasing concentrations of receptor agonist (Fig. 2) . Here, however, Ca 2+ basal levels did not increase over time, presumably because of the cell's capacity to produce and maintain a certain level of intracellular ATP assuring working plasma membrane (PM) and endoplasmic reticulum (ER) Ca 2+ -ATPases and better-controlled TRPM7 channel activity.
Clearly, in the case of thrombin stimulation, ATP availability is critical, as was confirmed in combined wholecell patch-clamp and Fura-2 experiments in overexpressing hTRPM7-HEK293 cells: Adding both GTP and ATP to the internal pipette solution even after 20 h of tetracycline induction not only restored thrombin-induced Ca 2+ release to control levels, but also inhibited hTRPM7 currents upon agonist exposure (Fig. 3) . hTRPM7 inhibition only occurred in cells that were still able to generate a Ca 2+ transient (15/21 cells; Table 1 ). hTRPM7 currents in cells that did not respond to thrombin were not inhibited (6/21 cells, Table 1 ), likely because of the break in signal transduction prior to activation of PLCβ and thereby preventing the reduction in PIP 2 levels in the vicinity of TRPM7 channels [9, 10] . We previously reported that thrombin had no inhibitory effect on native TRPM7-like currents [8] , however, these data were performed in the absence of intracellular Mg·ATP to allow full development of the small native currents. Adding Mg·ATP (1.5 mM) to the intracellular solution completely suppressed native hTRPM7 currents in non-induced HEK293 cells, and therefore thrombin-induced inhibition could not be assessed (Fig. 3) .
The requirement of ATP to compensate for a loss of Ca 2+ release when overexpressing hTRPM7 indicates involvement of the TRPM7 kinase domain in the process. Indeed, cells overexpressing a TRPM7 mutant with a point mutation that eliminates phosphorylation activity (hTRPM7-K1648R; [5] ), completely lacked intracellular Ca 2+ release (33/34 cells; Table 1 ; Fig. 3c ). Ca 2+ signaling can be inhibited at several steps of the GPCR signaling cascade. For example, desensitization of GPCRs can occur through phosphorylation by protein kinase C (PKC) or G protein-coupled receptor kinases (GRK), as well as allosteric binding of β-arrestin [26, 27] . However, suppression of thrombin receptor PAR-1 function by TRPM7 kinase phosphorylation seems unlikely, since hTRPM7-K1648R cells responded with suppressed Ca 2+ release regardless of which metabotropic GPCR was activated (Fig. 4a, b) . In addition, the reduction in GPCRinduced Ca 2+ release does not seem to be a tetracyclineinduced overexpression artifact as heterologous overexpression of human TRPM4, another protein of the TRPM family [16] , did not alter its Ca 2+ release signal to either of the agonists applied (Fig. 4c) . Finally, irreversibly activating G-proteins with the non-hydrolysable GTP-analog GTPγS (reviewed in [28] ) not only caused an initial Ca 2+ response in whole-cell patch-clamp experiments, but also produced significant Ca 2+ transients by a subsequent thrombin-receptor stimulation (Fig. 3d) . The latter also indicates that Ca 2+ stores properly refill through sarco-endoplasmic reticulum ATP (SERCA) pumps. Similarly, PLCβ and inositol triphosphate receptors (IP 3 R) appear fully functional in generating and responding to InsP 3 production (Fig. 3d) .
Heterotrimeric G-protein activation rests upon the ability of its Gα subunit to exchange GDP for GTP. This process is limited by Gα's intrinsic GTPase function that returns the G protein to its inactive state through GTP hydrolysis. GTPase activity, and with this G q inactivation, is strongly accelerated by binding to regulating effectors like GTPase-activating proteins (GAPs) and G protein-coupled receptor kinases (GRK) (reviewed in [29] ). The binding of these modulators is greatly facilitated by protein kinase A (PKA), which phosphorylates serine residues on regulators of G protein stimulation (RGS), a GAP member protein family, and GRK [30] . Serine phosphorylation of RGS proteins inhibits their ability to turn off GTPase-activity related to G q [31] . Since both the TRPM7 kinase phosphorylation activity needs to be preserved and, at least for thrombin receptors, sufficient ATP is needed to assure intact G q signaling, GAPs represent a plausible downstream target of TRPM7. Phospholipase C is a dual-function protein acting as lipase and as GAP [29] , and both PLCβ and PLCγ are known interaction partners of the TRPM7 serine/threonine kinase [9, 18] . Although PLCγ is not involved in GPCR signaling, it is known that TRPM7 kinase specifically phosphorylates PLCγ residues S1164 and T1045, which both are relevant in chicken B lymphocyte receptor signaling [18] . However, similar information awaits further study in regards to PLCβ.
Based on these observations, we propose that heterotrimeric G-proteins are targets of TRPM7 kinase phosphorylation activity, either directly, or through modulators of GTP hydrolysis.
